Clinicopathological classification and individualized treatment of breast cancer.
- Author:
Hui HU
1
;
Yin-hua LIU
;
Ling XU
;
Jian-xin ZHAO
;
Xue-ning DUAN
;
Jing-ming YE
;
Ting LI
;
Hong ZHANG
;
Shuang ZHANG
;
Yan XIONG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Breast Neoplasms; metabolism; Female; Humans; Immunohistochemistry; Male; Middle Aged; Receptor, Epidermal Growth Factor; metabolism; Receptors, Estrogen; metabolism; Receptors, Progesterone; metabolism; Retrospective Studies
- From: Chinese Medical Journal 2013;126(20):3921-3925
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDThe clinicopathological classification was proposed in the St. Gallen Consensus Report 2011. We conducted a retrospective analysis of breast cancer subtypes, tumor-nodal-metastatic (TNM) staging, and histopathological grade to investigate the value of these parameters in the treatment strategies of invasive breast cancer.
METHODSA retrospective analysis of breast cancer subtypes, TNM staging, and histopathological grading of 213 cases has been performed by the methods recommended in the St. Gallen International Expert Consensus Report 2011. The estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and Ki-67 of 213 tumor samples have been investigated by immunohistochemistry according to methods for classifying breast cancer subtypes proposed in the St. Gallen Consensus Report 2011.
RESULTSThe luminal A subtype was found in 53 patients (24.9%), the luminal B subtype was found in 112 patients (52.6%), the HER2-positive subtype was found in 22 patients (10.3%), and the triple-negative subtype was found in 26 patients (12%). Histopathological grade and TNM staging differed significantly among the four subtypes of breast cancer (P < 0.001).
CONCLUSIONIt is important to consider TNM staging and histopathological grading in the treatment strategies of breast cancer based on the current clinicopathological classification methods.